![](/img/cover-not-exists.png)
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
Li, D., Pant, S., Ryan, D.P., Laheru, D., Bahary, N., Dragovich, T., Hosein, P.J., Rolfe, L., Saif, M.W., LaValle, J., Yu, K.H., Lowery, M.A., Allen, A., O'Reilly, E.M.Volume:
14
Language:
english
Journal:
Pancreatology
DOI:
10.1016/j.pan.2014.07.003
Date:
September, 2014
File:
PDF, 222 KB
english, 2014